Dimerix Ltd
Research Dimerix Ltd (DXB) on Bullrun: market cap AUD 138.09M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDXB
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 138.09M
- Financial periodFY2025
- RevenueAUD 5.59M
- Revenue growth1271.1%
- Net income-AUD 13.25M
- Free cash flowAUD 39.03M
- Gross margin100.0%
Valuation Snapshot
latest market cap is AUD 138.09M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 5.59M | -AUD 13.25M | AUD 39.03M | 100.0% | -0.02 | AUD 68.28M | AUD 97.48K | AUD 13.38M |
| FY2024 | AUD 407.47K | -AUD 17.08M | -AUD 7.02M | 100.0% | -0.04 | AUD 22.14M | AUD 149.68K | AUD 18.19M |
| FY2023 | n/a | -AUD 13.80M | -AUD 12.73M | n/a | -0.04 | AUD 7.99M | AUD 5.96M | AUD 5.96M |
| FY2022 | n/a | -AUD 10.49M | -AUD 13.45M | n/a | -0.03 | AUD 9.63M | AUD 73.10K | AUD 14.42M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-06 | AUD 138.09M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Dimerix Ltd's market cap?
Dimerix Ltd's market capitalization is AUD 138.09M.
What does Dimerix Ltd do?
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.